Printer Friendly

THE LIPOSOME COMPANY APPOINTS DAVID SHAND TO BOARD OF DIRECTORS

 PRINCETON, N.J., Jan. 22 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO, LIPOZ), has appointed David G. Shand to its board of directors. He fills a new seat created through the expansion of the current board from eight to nine directors. Dr. Shand joined the company on Jan. 1 as executive vice president of research and development and chief scientific officer.
 Dr. Shand is responsible for all scientific activities at The Liposome Company, including research, development, and medical and regulatory affairs. Prior to joining The Liposome Company earlier this year, he was executive vice president of the Janssen Research Foundation, a Johnson and Johnson company.
 "We are very pleased to have Dr. Shand as an integral member of our executive team and our board of directors," Charles A. Baker, chairman and chief executive officer of The Liposome Company, said today. "His wealth of scientific knowledge, drug development experience, and managerial talent is already proving to be a valuable contribution to The Liposome Company."
 Prior to his tenure at Janssen, Dr. Shand was senior vice president, medical affairs worldwide, at Ayerst Laboratories, a division of American Home Products Corp. Before that, he was chief, Division of Clinical Pharmacology, Duke University Medical Center. Dr. Shand holds B.Sc., Ph.D., and M.B., B.S. degrees from St. Bartholomew's Hospital Medical College, London, England. He is a fellow of the Royal College of Physicians in England and is an author of more than 200 publications and abstracts.
 A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company develops proprietary parenteral pharmaceuticals for the treatment, prevention, and diagnosis of life-threatening diseases. It has four drugs currently in clinical trials. ABLC(TM) is in Phase II/III studies for the treatment of systemic fungal infections; TLC G-65 is in Phase II trials in the United States and Phase III in Europe for the treatment of Mycobacterium avium-intracellulare (MAI), an infection that eventually strikes 30 to 50 percent of people with AIDS; TLC D-99 is in Phase II for treatment of metastatic breast cancer; and TLC C-53 has just completed Phase I trials in preparation for studies in Adult Respiratory Distress Syndrome.
 -0- 1/22/93
 /CONTACT: Anne M. Van Lent, senior vice president of The Liposome Company, 609-452-7060/
 (LIPO)


CO: The Liposome Company, Inc. ST: New Jersey IN: MTC SU: PER

TS-GK -- NY010 -- 7833 01/22/93 10:33 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 22, 1993
Words:402
Previous Article:INTEGRATED HEALTH SERVICES OPENS 123 NEW MEDICAL SPECIALTY BEDS; COMPANY ALSO ACQUIRES LEASEHOLD INTEREST IN ALABAMA FACILITY
Next Article:APC HOLDING ANNOUNCES CASH TENDER OFFERING OF SUBSIDIARY
Topics:


Related Articles
TOP RESEARCHER JOINS THE LIPOSOME COMPANY CELL ADHESION SCIENTIFIC ADVISORY BOARD
FORMER MERCK EXECUTIVE APPOINTED TO LIPOSOME COMPANY BOARD OF DIRECTORS
THE LIPOSOME COMPANY APPOINTS NEW MANUFACTURING EXECUTIVE
LIPOSOME COMPANY NAMES SILVERMAN VP OF STRATEGIC PLANNING
ANDREW JANOFF AND JOEL PORTNOFF NAMED VICE PRESIDENTS AT THE LIPOSOME COMPANY
THE LIPOSOME COMPANY APPOINTS VICE PRESIDENT, INTERNATIONAL OPERATIONS
THE LIPOSOME COMPANY, INC. PROMOTES TWO EXECUTIVES; SILVERMAN, WILLIAMS NAMED TO NEW MANAGEMENT POSTS
THE LIPOSOME COMPANY ANNOUNCES RESEARCH MANAGEMENT REALIGNMENT
THE LIPOSOME COMPANY APPOINTS JOSEPH STEWART TO ITS BOARD OF DIRECTORS
THE LIPOSOME COMPANY ANNOUNCES NEW MANAGEMENT APPOINTMENTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters